Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia

Ponatinib is a third line drug for the treatment of chronic myeloid leukemia patients, especially those that develop the gatekeeper mutation T315I, which is resistant to the first and the second line drugs imatinib, nilotinib, dasatinib and bosutinib. The compound was first identified as a pan Bcr-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Musumeci, Francesca, Greco, Chiara, Grossi, Giancarlo, Molinari, Alessio, Schenone, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267038/
https://www.ncbi.nlm.nih.gov/pubmed/30423915
http://dx.doi.org/10.3390/cancers10110430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267038/
https://www.ncbi.nlm.nih.gov/pubmed/30423915
http://dx.doi.org/10.3390/cancers10110430

Ejemplares similares